Immunotherapy of peritoneal carcinomatosis

Peritoneal Carcinomatosis: A Multidisciplinary Approach

Volumn , Issue , 2007, Pages 483-491

  Ströhlein, Michael A ^a   Heiss, Markus M ^a  

^a UNIVERSITY OF WITTEN HERDECKE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CYTOKINE;

CARCINOMA; DRUG EFFECT; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; METHODOLOGY; PERITONEAL CAVITY; PERITONEUM; PERITONEUM TUMOR; REVIEW; T LYMPHOCYTE;

ANTIBODIES; CARCINOMA; CYTOKINES; HUMANS; IMMUNOTHERAPY; PERITONEAL CAVITY; PERITONEAL NEOPLASMS; PERITONEUM; T-LYMPHOCYTES;

EID: 57749187042     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-0-387-48993-3_33     Document Type: Chapter

References (22)

1. Kubicka U, Olszewski WL, Tarnowski W, Bielecki K, Ziolkowska A, Wierzbicki Z (1996) Normal human immune peritoneal cells: subpopulations and functional characteristics. Scand J Immunol 44:157-163
2. Tellado JM, Broche F (2001) Defense mechanisms of the peritoneal cavity. Curr Opin Crit Care 7(2):105-116
3. Jayne DG, Perry SL, Morrison E, Farmery SM, Guillou PJ (2000) Activated mesothelial cells produce heparin-binding growth factors: implications for tumour metastases. Br J Cancer 82:1233-1238
4. Yamaguchi Y, Ohshita A, Kawabuchi Y, Hihara J, Miyahara E, Toge T (2004) Locoregional immunotherapy of malignant ascites from gastric cancer using DTH-oriented doses of the streptococcal preparation OK-432: Treatment of Th1 dysfunction in the ascites microenvironment. Int J Oncol 24:959-966
5. Freedman RS, Vadhan-Raj S, Butts C, Savary C, Melichar B, Verschraegen C, Kavanagh JJ, Hicks ME, Levy LB, Folloder JK, Garcia ME (2003) Pilot Study of Flt3 Ligand Comparing Intraperitoneal with Subcutaneous Routes on Hematologic and Immunologic Responses in Patients with Peritoneal Carcinomatosis and Mesotheliomas. Clin Cancer Res 9:5228-5237
6. Eggermont AM, Sugarbaker PH (1987) Lymphokine-activated killer cell and interleukin-2 inhibitors: their role in adoptive immunotherapy. Cell Immunol 107:384-394
7. Ottow RT, Steller EP, Sugarbaker PH, Wesley RA, Rosenberg SA (1987) Immunotherapy of intraperitoneal cancer with interleukin 2 and lymphokineactivated killer cells reduces tumor load and prolongs survival in murine models. Cell Immunol 104:366-376
8. Perrin P, Cassagnau E, Burg C, Patry Y, Vavasseur F, Harb J, Le Pendu J, Douillard JY, Galmiche JP, Bornet F (1994) An interleukin 2/sodium butyrate combination as immunotherapy for rat colon cancer peritoneal carcinomatosis. Gastroenterology 107:1697-1708
9. Sartori S, Nielsen I, Tassinari D, Trevisani L, Abbasciano V, Malacarne P (2001) Evaluation of a standardized protocol of intracavitary recombinant interferon alpha-2b in the palliative treatment of malignant peritoneal effusions. A prospective pilot study. Oncology 61:192-196
10. Litvinov SV, Velders MP, Bakker HA, Fleuren GJ, Warnaar SO (1994) Ep-CAM: a human epithelial antigen is a homophilic cell-cell adhesion molecule. J Cell Biol 125:437-446
11. Piso P, Aselmann H, von Wasielewski R, Dahlke MH, Klempnauer J, Schlitt HJ (2003) Prevention of peritoneal carcinomatosis from human gastric cancer cells by adjuvant-type intraperitoneal immunotherapy in a SCID mouse model. Eur Surg Res 35:470-476
12. Andersson H, Lindegren S, Back T, Jacobsson L, Leser G, Horvath G (2000) Radioimmunotherapy of nude mice with intraperitoneally growing ovarian cancer xenograft utilizing 211At-labelled monoclonal antibody MOv18. Anticancer Res 20:459-462
13. Kinuya S, Li XF, Yokoyama K, Mori H, Shiba K, Watanabe N, Shuke N, Bunko H, Michigishi T, Tonami N (2003) Intraperitoneal radioimmunotherapy in treating peritoneal carcinomatosis of colon cancer in mice compared with systemic radioimmunotherapy. Cancer Sci 94:650-654
14. Muto MG, Finkler NJ, Kassis AI, Howes AE, Anderson LL, Lau CC, Zurawski VR, Jr., Weadock K, Tumeh SS, Lavin P (1992) Intraperitoneal radioimmunotherapy of refractory ovarian carcinoma utilizing iodine-131-labeled monoclonal antibody OC125. Gynecol Oncol 45:265-272
15. Wunderlich JR, Mezzanzanica D, Garrido MA, Neblock DS, Daddona PE, Andrew SM, Zurawski VR, Jr., Canevari S, Colnaghi MI, Segal DM (1992) Bispecific antibodies and retargeted cellular cytotoxicity: novel approaches to cancer therapy. Int J Clin Lab Res 22:17-20
16. Marme A, Strauss G, Bastert G, Grischke EM, Moldenhauer G (2002) Intraperitoneal bispecific antibody (HEA125xOKT3) therapy inhibits malignant ascites production in advanced ovarian carcinoma. Int J Cancer 101:183-189
17. Lindhofer H, Mocikat R, Steipe B, Thierfelder S (1995) Preferential speciesrestricted heavy/light chain pairing in rat/mouse quadromas. Implications for a single-step purification of bispecific antibodies. J Immunol 155:219-225
18. Zeidler R, Reisbach G, Wollenberg B, Lang S, Chaubal S, Schmitt B, Lindhofer H (1999) Simultaneous activation of T cells and accessory cells by a new class of intact bispecific antibody results in efficient tumor cell killing. J Immunol 163:1246-1252
19. Zeidler R, Mysliwietz J, Csanady M, Walz A, Ziegler I, Schmitt B, Wollenberg B, Lindhofer H (2000) The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells. Br J Cancer 83:261-266
20. Ruf P, Lindhofer H (2001) Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody. Blood 98:2526-2534
21. Heiss MM, Strohlein MA, Jager M, Kimmig R, Burges A, Schoberth A, Jauch KW, Schildberg FW, Lindhofer H (2005) Immunotherapy of malignant ascites with trifunctional antibodies. Int J Cancer 117:435-443
22. Strohlein MA, Gruetzner KU, Tarabichi A, Jauch KW, Bartelheim H, Lindhofer H, von Roemeling R, Heiss MM (2006) Efficacy of intraperitoneal treatment with the trifunctional antibody catumaxomab in patients with GItract cancer and peritoneal carcinomatosis: A matched pair analysis. J Clin Oncol 24:111